Business Update Positive

2026-11-06 16:39

- Shaily Engineering Plastics Limited has incorporated a wholly owned subsidiary named Shaily Medtech Devices Manufacturing Ltd in Abu Dhabi, UAE on November 06, 2026. - The new subsidiary will focus on the manufacturing of medical devices (Pen Injectors). - The initial cash subscription by the company amounts to AED 1,000,000 for a 100% shareholding.

Business Update Positive

2026-11-06 16:29

- Shaily Engineering Plastics Ltd incorporated a wholly owned subsidiary named 'Shaily Medtech Devices Manufacturing Ltd' in Abu Dhabi, UAE on November 06, 2026. - The new subsidiary will focus on the manufacturing of medical devices (Pen Injectors). - Initial subscription amounting to AED 10,00,000 will be made in cash through banking channels for 100% shareholding.

Business Update Positive

2026-11-06 12:58

Current scenario - Consolidated revenue for Q2 FY27 reached INR320 crores, up 24% YoY and 14% QoQ, driven by strong growth in the Healthcare segment. - EBITDA rose 25% YoY and 22% QoQ to INR102 crores, crossing the INR100 crore milestone for the first time with an EBITDA margin of 31.9%. - Healthcare is now the primary growth engine, contributing 55% of revenue and growing 78% YoY, delivering 10.4 million devices in the quarter. - Consumer business has stabilized over two sequential quarters though it remains below last year's levels due to subdued demand in Europe and the U.S. Management Guidance & Outlook - Company remains on track to exceed its full-year device guidance of 36 million units. - Commercial supplies for semiconductor trays are expected to commence in Q4 FY27 from the existing facility, with trial production starting in Q3. - The UK subsidiary is expected to be EBITDA and PAT positive for the full year. Growth Drivers - Global GLP-1 market transition and patent expiries are driving higher volume demand and patient access for drug delivery devices. - Launch of 'Toby Reusable', a 2-step reusable auto-injector for next-generation GLP-1 therapies, offering 70% better sustainability compared to disposable auto-injectors. - Expansion into new therapeutic areas like emergency use and oncology, along with scaling up consumer electronics and semiconductor packaging opportunities.

Financials Positive

2026-11-06 12:48

Q2 FY27 Consolidated Revenue ₹320Cr vs ₹257Cr (▲24.5% YoY) EBITDA ₹102Cr vs ₹82Cr (▲24.4% YoY) PAT ₹61Cr vs ₹51Cr (▲19.6% YoY) EBITDA Margin 31.9% vs 31.8% (▲10bps) Healthcare revenue surged 78% YoY to ₹175Cr, now contributing 55% of total revenue. Management remains confident in exceeding full-year device guidance of 36 million pens and scaling new platforms like Toby Reusable, emergency use, and oncology.

Business Update Neutral

2026-10-30 21:02

- Shaily Engineering Plastics Limited informed the exchanges about the audio recording of the earnings call held on October 30, 2026. - The recording has been made available on the company's official website. - The transcript of the earnings call is stated to be submitted separately in due course.

Business Update Neutral

2026-10-30 20:51

- Shaily Engineering Plastics Limited has submitted the audio recording of the earnings call held on 30th October 2026. - The audio recording is accessible on the company's official website. - The transcript of the earnings call will be submitted separately in due course.

Business Update Positive

2026-10-29 19:08

- Shaily Engineering Plastics released its Q2 & H1 FY27 Investor Presentation highlighting strong operational and financial performance. - Healthcare segment revenue surged 78% YoY to ₹175.1 Cr, driven by Semaglutide pens supply and new contracts. - Announced plans to set up a medical devices manufacturing facility in Abu Dhabi with an investment of AED 130-150 million (~₹350 Cr) to add 75 million pens annual capacity. - Q2 FY27 Consolidated Revenue stood at ₹319.5 Cr (up 24% YoY), with EBITDA at ₹101.8 Cr (up 25% YoY) and PAT at ₹61.3 Cr (up 20% YoY). - CARE Ratings upgraded the company's short-term bank facilities to CARE A1+.

Business Update Positive

2026-10-29 19:07

- Shaily Engineering Plastics Ltd released its Q2 & H1 FY27 Investor Presentation highlighting strong performance driven by the healthcare segment. - Q2 FY27 Consolidated Revenue stood at ₹319.5Cr vs ₹256.7Cr (▲24% YoY). - EBITDA reached ₹101.8Cr vs ₹81.6Cr (▲25% YoY) with an EBITDA margin of 31.9%. - Profit After Tax (PAT) grew by 20% YoY to ₹61.3Cr compared to ₹51.3Cr in Q2 FY26. - Key developments include the launch of 'Shaily AI Toby' reusable auto-injector pen for GLP-1 therapies, capacity expansion of 25 Mn pens, and plans to set up a new medical device facility in Abu Dhabi with an investment of ~₹350 Crores.

Governance Neutral

2026-10-29 18:46

- Shaily Engineering Plastics Limited has allotted 1,300 equity shares of face value ₹2/- each under the Shaily Employee Stock Option Plan 2019. - Exercise price is ₹732/- per equity share, realizing a total money of ₹9,51,600/-. - Consequent to this allotment, the issued and paid-up equity share capital increased from ₹9,19,90,496 to ₹9,19,93,096/-.

Routine Neutral

2026-10-29 18:44

- Shaily Engineering Plastics Ltd has announced the allotment of 1,300 equity shares of face value ₹2/- each under the Shaily Employee Stock Option Plan 2019. - The exercise price is ₹732/- per equity share, realizing a total money of ₹9,51,600/-. - Post-allotment, the issued and paid-up equity share capital stands increased to ₹9,19,93,096/- divided into 4,59,96,548 equity shares.

Financials Neutral

2026-10-29 18:30

- Unaudited standalone and consolidated financial results submitted for the quarter ended September 30, 2026. - Statutory auditor B S R and Co issued an unmodified review report with no qualifications. - Financial statement tables are omitted from the provided filing extract.

Financials Neutral

2026-10-29 18:24

- Board approved Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. - Statutory Auditors B S R and Co issued an unmodified Limited Review Report on both Standalone and Consolidated Results. - Detailed financial result tables were not provided in the disclosure document.

Financials Neutral

2026-10-29 18:15

- Board of Directors approved Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. - Statutory auditors B S R and Co issued Limited Review Reports with an unmodified conclusion. - Detailed financial figures and tables were omitted from the provided document.

Business Update Neutral

2026-10-22 16:41

Concall Schedule Concall Date: 30th October 2026 Concall Time: 04:00 p.m., IST

Business Update Neutral

2026-10-22 16:28

Concall Schedule Concall Date: 30th October 2026 Concall Time: 04:00 p.m., IST

Governance Neutral

2026-10-21 17:08

- Shaily Engineering Plastics Ltd has informed that a meeting of the Board of Directors is scheduled to be held on Thursday, 29th October 2026. - The board will consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2026. - The trading window for dealing in securities of the company remains closed from 1st October 2026 to 31st October 2026 (both days inclusive).

Governance Positive

2026-09-30 10:26

- Shaily Engineering Plastics Limited held its 46th Annual General Meeting (AGM) on September 28, 2026. - All resolutions related to the adoption of financial statements, dividend declaration, and re-appointment of directors were passed with requisite majority. - Voting results and Scrutinizer's Report were submitted in compliance with SEBI regulations.

Governance Positive

2026-09-28 17:00

- Shaily Engineering Plastics Ltd held its 46th Annual General Meeting (AGM) on September 28, 2026. - Shareholders approved the audited standalone and consolidated financial statements and a dividend for FY 2025-26. - Re-appointed Mr. Mahendra Sanghvi and Mr. Amit Mahendra Sanghvi (Managing Director for 5 years), and passed an enabling resolution to raise up to ₹500 crore through securities. - FY2025-26 performance highlights: Revenue grew 25.91% to ₹990.67 crore, EBITDA rose 61.28% to ₹287.70 crore (29.0% margin), and net profit surged 82.5% to ₹169.91 crore.

Financials Positive

2026-09-26 16:09

- Shaily Engineering Plastics Limited has informed about credit ratings reviewed by CARE Ratings Limited. - Long Term Bank Facilities amounting to ₹239.24 crore reaffirmed at CARE A+; Stable. - Short Term Bank Facilities amounting to ₹35.00 crore upgraded from CARE A1 to CARE A1+.

Financials Positive

2026-09-26 15:56

- CARE Ratings has reaffirmed the long-term bank facilities rating at CARE A+ with a Stable outlook for ₹239.24 crore. - Short-term bank facilities rating of ₹35.00 crore has been upgraded from CARE A1 to CARE A1+.

Routine Neutral

2026-09-26 10:33

- Trading window to close from Thursday, October 01, 2026. - Closure will remain effective until 48 hours after declaration of Q2 Unaudited Financial Results ending September 30, 2026. - Date of the Board Meeting will be informed separately.

Routine Neutral

2026-09-26 10:20

- Trading window closed from October 01, 2026. - Closure remains effective until 48 hours after declaration of Q2 Unaudited Financial Results for the quarter ending September 30, 2026. - Date of the Board Meeting will be intimated separately.

Business Update Neutral

2026-09-21 20:02

- Investor Meeting Schedule: - Meeting Date: Wednesday, 23rd September 2026 - Organized By: JP Morgan - Nature of Meeting: 1 x 1 / Group Meeting - Place: Ahmedabad

Business Update Neutral

2026-09-21 19:58

- Investor Meeting Schedule - Meeting Date: Wednesday, 23rd September 2026 - Organized By: JP Morgan - Nature of Meeting: 1 x 1 / Group Meeting - Place: Ahmedabad

Governance Positive

2026-09-04 18:18

- 46th Annual General Meeting (AGM) to be held on Monday, September 28, 2026, at 11:00 a.m. IST via Video Conferencing/OAVM. - Agenda includes adopting FY26 financial statements and declaring a dividend of ₹3/- per equity share for FY26. - Also includes re-appointment of directors and an enabling resolution to raise up to ₹500 Cr.

Business Update Neutral

2026-09-04 17:45

- Submission of Business Responsibility and Sustainability Report (BRSR) for the Financial Year ended March 31, 2026. - Exports contributed 67.7% of the total turnover for FY 2025-26. - The company achieved zero fatalities in FY 2025-26, underscoring its commitment to employee protection. - No monetary fines or penalties were paid in the financial year.

Business Update Neutral

2026-08-17 20:00

- Schedule of Analyst / Institutional Investor Group Meeting - Date: 21st August 2026 - Time: 10:00 AM onwards - Venue: Baroda, Gujarat

Business Update Neutral

2026-08-17 19:56

- Schedule of Analyst / Institutional Investor Meeting - Meeting Date: 21st August 2026 - Meeting Time: 10:00 AM onwards - Nature of Meeting: Group Meeting - Venue: Baroda, Gujarat

Business Update Positive

2026-08-17 19:38

- Additional 25 million pen capacity expected operational by September end, increasing total pen injector capacity to approximately 75 million pens per annum. - Management is confident of exceeding full year guidance for pen sales, anticipating beyond 36 million units. - Gross margin, which saw a sequential decline in Q1 due to commodity prices and freight, is expected to normalize by Q3. - Healthcare segment is now the largest business segment (51% of revenue) and is expected to continue robust growth. - Developing new products including reusable auto-injectors (testing soon, showcasing at CPHI Milan), emergency use auto-injectors (program closure by end of FY27), and on-body injectors. - Plans for a new Consumer Electronics plant with an investment of ₹80-100 crores and ₹5 crores for Semiconductor Trays in existing facility. - Appointed dedicated business development heads for Europe and North America to pursue partnerships with major global pharmaceutical companies.

Business Update Positive

2026-08-17 19:34

- Q1 FY27 Consolidated Revenue ₹281Cr vs ₹247Cr (▲14% YoY) - EBITDA ₹83Cr vs ₹70Cr (▲18% YoY), EBITDA Margin 29.7% vs 28.3% (▲120bps) - PAT ₹48Cr vs ₹41Cr (▲17% YoY), PAT Margin 17.1% vs 16.6% (▲40bps) - Healthcare segment revenue grew 85% YoY to ₹142Cr, becoming 51% of consolidated revenue. - Industrial segment revenue grew 25% YoY to ₹23Cr. - Consumer segment revenue declined 24% YoY to ₹116Cr due to softer demand in Europe and US. Management expects this segment to maintain FY26 levels this year. - Additional 25 million pen capacity expected operational by end of September 2026, increasing total installed capacity to ~75 million pens per annum. - Management expects to exceed the full year pen guidance of 36 million. - Gross margins, which saw a sequential decline due to commodity and freight prices, are expected to normalize by Q3 FY27. - Actively working on new healthcare products: emergency use auto-injectors (closure by end of FY27), reusable auto-injectors (launching by year-end), and on-body injectors. - Secured first tentative U.S. FDA approval for generic Semaglutide and launched in multiple markets. - Appointed business development heads for Europe and North America to secure partnerships with major global pharmaceutical companies (announcement expected in 4-6 quarters for innovator segment). - Won a global project from an FMCG customer and new business in LED lighting; secured new projects from Appliance & Automotive customers and onboarded a new customer for 5 Consumer Electronic components. - Planning investment of ₹5Cr in existing facility for Semiconductor Trays and ₹80-100Cr for a new Consumer Electronics plant in South India. - Approximately 50-55% of the Abu Dhabi plant capacity is committed, with the plant expected to commence sales by end of FY28.

Business Update Neutral

2026-08-10 20:29

- Audio recording of the Earnings Call held on August 10, 2026, has been uploaded to the company's website. The transcript of the call will be submitted separately.

Business Update Neutral

2026-08-10 20:27

- Audio recording of the Earnings Call held on 10th August 2026 is available on the company website. The transcript will be submitted separately.

Governance Positive

2026-08-08 19:38

- Board Meeting on August 8, 2026: Approved Q1 FY27 financial results; Re-appointed MD Amit Mahendra Sanghvi for 5 years (Oct 2026-Sep 2031). - Fixed September 11, 2026, as Record Date for FY26 final dividend; Approved revised Insider Trading Code.

Financials Positive

2026-08-08 19:33

- Q1 FY27 Consolidated Revenue ₹280.7Cr vs ₹246.7Cr (▲14% YoY) - EBITDA ₹83.3Cr vs ₹70.4Cr (▲18% YoY) - PAT ₹48.0Cr vs ₹41.1Cr (▲17% YoY) - EBITDA Margin 29.7% vs 28.5% (▲120bps)

Governance Positive

2026-08-08 19:31

- The Board of Directors considered and approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. - Mr. Amit Mahendra Sanghvi was re-appointed as Managing Director for a term of 5 years, effective from October 1, 2026, to September 30, 2031. - Friday, September 11, 2026, was fixed as the Record Date for determining members entitled to receive the final dividend for FY 2025-26. - The revised Code of Conduct for Prevention of Insider Trading in the Securities of the Company was approved.

Governance Positive

2026-08-08 19:29

- Board approved unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. - Re-appointed Mr. Amit Mahendra Sanghvi as Managing Director for a term of 5 years, effective October 1, 2026, to September 30, 2031. - Fixed September 11, 2026, as the Record Date for determining members entitled to receive the final dividend for FY 2025-26. - Approved revised Code of Conduct for Prevention of Insider Trading.

Governance Positive

2026-08-08 19:17

- Board meeting held on August 08, 2026, approved Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. - Re-appointed Mr. Amit Mahendra Sanghvi as Managing Director from October 01, 2026, to September 30, 2031. - Fixed September 11, 2026, as the Record Date for the final dividend for FY 2025-26. - Approved the revised Code of Conduct for Prevention of Insider Trading.

Financials Positive

2026-08-08 19:11

- Board approved Q1 FY27 (June 30, 2026) Unaudited Standalone & Consolidated Financial Results. - Fixed September 11, 2026, as Record Date for final dividend for FY 2025-26. - Approved re-appointment of Mr. Amit Mahendra Sanghvi as MD (Oct 1, 2026 - Sep 30, 2031), subject to shareholder approval.

Financials Positive

2026-08-08 19:01

- Q1 FY27 Consolidated Revenue ₹280.7Cr vs ₹246.7Cr (▲14% YoY) - EBITDA ₹83.3Cr vs ₹70.4Cr (▲18% YoY) - PAT ₹48.0Cr vs ₹41.1Cr (▲17% YoY) - EBITDA Margin 29.7% vs 28.5% (▲120bps) - Healthcare segment revenue grew by 85% YoY, driving overall growth. - Received customer approvals for Semaglutide pens in Canada/Brazil and new projects in IP-led platforms. - Secured a global project from an FMCG customer and new projects in LED lights. - Confirmed new projects from Appliance and Automotive customers and five new parts for Consumer Electronics.

Financials Positive

2026-08-08 18:57

- Q1 FY27 Consolidated Revenue ₹280.57 Cr vs ₹246.69 Cr (▲13.73% YoY) - EBITDA ₹83.05 Cr vs ₹68.40 Cr (▲21.42% YoY) - PAT ₹48.01 Cr vs ₹41.12 Cr (▲16.76% YoY) - EBITDA Margin 29.60% vs 27.73% (▲187 bps)

Financials Positive

2026-08-08 18:49

- Q1 FY27 Consolidated Revenue ₹280.57Cr vs ₹246.69Cr (▲13.73% YoY) - EBITDA ₹83.05Cr vs ₹68.40Cr (▲21.42% YoY) - PAT ₹48.01Cr vs ₹41.12Cr (▲16.75% YoY) - EBITDA Margin 29.60% vs 27.72% (▲188bps)

Financials Positive

2026-08-08 18:46

- Q1 FY27 Consolidated Revenue ₹280.57Cr vs ₹246.69Cr (▲13.73% YoY) - EBITDA ₹83.05Cr vs ₹68.40Cr (▲21.42% YoY) - PAT ₹48.01Cr vs ₹41.12Cr (▲16.76% YoY) - EBITDA Margin 29.60% vs 27.73% (▲187bps) - Board approved the re-appointment of Mr. Amit Mahendra Sanghvi as Managing Director for a term of 5 years, effective from October 1, 2026, to September 30, 2031. - The Record Date for determining members entitled to receive the final dividend for FY 2025-26 has been fixed as Friday, September 11, 2026.

Financials Positive

2026-08-08 18:41

- Q1 FY27 Consolidated Revenue ₹280.57Cr vs ₹246.69Cr (▲14% YoY) - EBITDA ₹83.30Cr vs ₹70.49Cr (▲18% YoY) - PAT ₹48.01Cr vs ₹41.12Cr (▲17% YoY) - EBITDA Margin 29.7% vs 28.6% (▲110bps) - Record Date: September 11, 2026, for final dividend for FY 2025-26. - Mr. Amit Mahendra Sanghvi re-appointed as Managing Director for 5 years (Oct 2026 - Sep 2031). - Board approved revised Code of Conduct for Prevention of Insider Trading.

Business Update Neutral

2026-08-03 16:10

- Concall Schedule - Concall Date: 10th August 2026 - Concall Time: 4:00 PM, IST - Purpose: To discuss Q1 FY27 financial performance (quarter ended June 30, 2026).

Governance Neutral

2026-07-31 17:19

- Board meeting on August 8, 2026, to approve Q1 FY27 financial results (quarter ended June 30, 2026). - Trading window closure from July 1, 2026, to August 10, 2026. - Company to publish financial results in Crores instead of Lacs, effective Q1 FY27.

Business Update Neutral

2026-07-06 16:44

- Investor Meetings Schedule - Date: 13th & 14th July 2026 - Time: 10:00 AM to 6:00 PM - Nature of Meeting: 1x1/ Group Meeting - Organised by: UBS - Venue: London, UK

Business Update Neutral

2026-07-06 16:39

- Concall Schedule - Concall Date: 13th & 14th July 2026 - Concall Time: 10:00 AM to 6:00 PM - Additional details: 1x1/Group Meetings organised by UBS in London, UK.

Routine Neutral

2026-06-25 16:15

- Trading window for persons covered under the code will remain closed from July 01, 2026. - It will reopen 48 hours after the declaration of Unaudited Financial Results for the quarter ended June 30, 2026. - Board Meeting date for results will be intimated separately.

Ownership Neutral

2026-06-25 16:10

- Trading window for insiders to close from July 01, 2026. - Reopens 48 hours post declaration of Unaudited Financial Results for quarter ending June 30, 2026. - Board Meeting date for results will be intimated separately.

Ownership Negative

2026-06-19 11:52

- Promoter group member, Vanita L. Nagda, disposed of 1,043,510 equity shares (2.27% of total equity) of Shaily Engineering Plastics Ltd. - The sale was conducted via Open Market on June 18, 2026.

Business Update Neutral

2026-06-12 15:01

- Concall Schedule - Concall Date: 16th June 2026 - Concall Time: 10:00 AM to 6:00 PM - Nature of Meeting: 1x1/ Group Meeting - Organised by: Systematix - Venue: Taj Santacruz, Mumbai

Business Update Neutral

2026-06-12 14:53

- Investor Meeting Schedule - Meeting Date: 16th June 2026 - Meeting Time: 10:00 AM to 6:00 PM - Venue: Taj Santacruz, Mumbai - Organized by: Systematix

Business Update Positive

2026-05-27 12:15

Shaily Engineering Plastics reported strong growth in its Healthcare and Industrial segments, driven by new product launches, market entries in Canada and the semiconductor supply chain, and new customer acquisitions. The Consumer segment experienced a degrowth due to global demand slowdown and geopolitical tensions. Operational efficiency improved, with healthcare manufacturing rejection rates dropping to 8% from 30%. Management guided for 36 million pen units for FY27 and 50 million for FY28, with margins expected to be sustainable and improving year-on-year. The company plans an initial Capex of INR100 crores for a new consumer electronics plant and has an enabling resolution to raise up to INR500 crores for future growth. Key priorities include scaling healthcare, building the Abu Dhabi facility, and ramping up new programs. The company secured an incremental INR423 crore pen injector order over four years. Debt-to-equity stands at 0.3x.

Business Update Neutral

2026-05-26 09:53

Shaily Engineering Plastics Ltd has intimated a schedule of an Analyst / Institutional Investor Group Meeting to be held on 30th May 2026, from 10:00 AM onwards in Baroda, Gujarat. Discussions will be based on publicly available information, and no Unpublished Price Sensitive Information (UPSI) will be discussed.

Business Update Neutral

2026-05-22 15:34

Shaily Engineering Plastics Limited has intimated the schedule for an Analyst / Institutional Investor Meeting. The company's officials will attend a 1x1/Group Meeting at the Investors Conference organized by 360 ONE Capital (B&K) on 28th May 2026, from 11:00 AM to 5:00 PM, at Grand Hyatt, Mumbai. Discussions will be based on publicly available information.

Business Update Neutral

2026-05-20 22:58

Shaily Engineering Plastics Ltd has informed that the audio recording of the earnings call held on 20th May 2026 is now available on the company's website. This follows previous intimations regarding the earnings call and investor presentation. The company also stated that the transcript of the call will be submitted separately.

Business Update Positive

2026-05-20 15:17

Shaily Engineering Plastics Limited announced the launch of a customer combination product incorporating its ShailyPen Neo™ device technology in Canada, following its commercial availability in India since March 2026. This launch is supported by USFDA Tentative Approval, Health Canada Notice of Compliance, and Indian Regulatory Approval for the generic Semaglutide injection, for which Shaily provides the device components.

Financials Positive

2026-05-19 21:14

Shaily Engineering Plastics reported Standalone Revenue ₹224.07Cr vs ₹203.28Cr (▲10.22% YoY), EBITDA ₹76.48Cr vs ₹52.40Cr (▲45.95% YoY), and PAT ₹48.68Cr vs ₹29.53Cr (▲64.88% YoY) for the quarter ended March 31, 2026. EBITDA Margin expanded to 34.13% vs 25.78% (▲835bps). The Board also recommended a final dividend of ₹3/- per share and approved an enabling resolution to raise up to ₹500 Cr for business expansion into high-growth adjacencies like healthcare, consumer electronics, and semiconductor components.

Ownership Neutral

2026-05-19 20:24

Shaily Engineering Plastics Ltd announced the allotment of 40,155 fully paid-up equity shares (face value Rs. 2/- each) on May 19, 2026. These shares were issued to eligible employees upon the exercise of stock options under the ESOP Plan 2019, at exercise prices of Rs. 732/- and Rs. 684/- per share. Consequently, the company's issued and paid-up equity share capital has increased from 4,59,55,093 to 4,59,95,248 equity shares.

Governance Positive

2026-05-19 20:14

Shaily Engineering Plastics Limited's Nomination and Remuneration Committee approved the grant of 3,000 Stock Options to eligible employees on May 19, 2026, under the Shaily Employee Stock Option Plan 2019. The options will vest 1/3 each year over three years and can be exercised within four years from the vesting date, with the pricing formula set at 1/3rd of the market price on the vesting date.

Financials Positive

2026-05-19 19:10

Consolidated Revenue ₹236.8 Cr vs ₹217.8 Cr (▲9% YoY), EBITDA ₹69.3 Cr vs ₹54.6 Cr (▲27% YoY), PAT ₹40.2 Cr vs ₹28.6 Cr (▲40% YoY). EBITDA Margin 29.3% vs 25.1% (▲420 bps). The company also announced a significant order win of ₹423 crore for pen injectors over four years, commenced commercial supplies to a consumer electronics customer, and signed an agreement for semiconductor trays.

Governance Positive

2026-05-19 18:21

The Board of Directors of Shaily Engineering Plastics Limited met on May 19, 2026. Key outcomes include the approval of Audited Standalone & Consolidated Financial Results for the quarter and year ended March 31, 2026, and a recommendation of a Final Dividend of ₹3/- (150%) per equity share. The Board also approved the appointment of new Internal and Cost Auditors for FY2026-27, and Mr. Chi Hung Kam as Chief Operating Officer – Healthcare. An enabling resolution was passed to raise funds up to ₹500 Crores to support business growth and diversification into new areas like consumer electronics and semiconductor components.

Financials Positive

2026-05-19 18:01

Standalone Revenue ₹224.07Cr vs ₹203.28Cr (▲10.2% YoY), EBITDA ₹62.83Cr vs ₹47.86Cr (▲31.3% YoY), PAT ₹48.68Cr vs ₹29.53Cr (▲64.9% YoY). EBITDA Margin 28.0% vs 23.5% (▲450bps).

Financials Positive

2026-05-19 17:56

Standalone Revenue ₹224Cr vs ₹203Cr (▲10% YoY), EBITDA ₹63Cr vs ₹48Cr (▲31% YoY), PAT ₹49Cr vs ₹30Cr (▲65% YoY) for the quarter ended March 31, 2026. EBITDA Margin stood at 28% vs 24% (▲400bps). The Board also recommended a final dividend of ₹3/- per equity share and approved an enabling resolution to raise up to ₹500Cr for business expansion and diversification into high-growth sectors like consumer electronics and semiconductors.

Financials Positive

2026-05-19 17:54

Standalone Revenue ₹224.07 Cr vs ₹203.28 Cr (▲10.22% YoY), EBITDA ₹76.48 Cr vs ₹52.40 Cr (▲45.95% YoY), PAT ₹48.68 Cr vs ₹29.53 Cr (▲64.87% YoY). EBITDA Margin 34.13% vs 25.78% (▲835bps).

Business Update Neutral

2026-05-15 13:57

Shaily Engineering Plastics Limited will host an earnings conference call with analysts and investors on Wednesday, May 20, 2026, at 4:00 PM IST. The call is scheduled to discuss the operational and financial performance for the quarter and fiscal year ended March 31, 2026. Key participants will include Mr. Amit Sanghvi (Managing Director) and Mr. Sanjay Shah (Chief Strategy Officer).

Business Update Neutral

2026-04-28 10:36

Shaily Engineering Plastics Limited responded to NSE/BSE queries regarding significant share price movement on April 27, 2026, stating the movement is purely market driven and confirming no undisclosed material events requiring disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015.

Routine Neutral

2026-04-27 19:59

New Filing detected. See link for details.

Routine Neutral

2026-04-07 16:00

Shaily Engineering Plastics Ltd. submitted a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. The certificate confirms the processing of dematerialized securities and updating of the register of members.

Routine Neutral

2026-03-25 14:18

Shaily Engineering Plastics Limited announced the closure of the trading window from April 1, 2026, until 48 hours after the declaration of audited standalone and consolidated financial results for the year ending March 31, 2026. The Board meeting date for these results will be intimated separately.

Business Update Neutral

2026-03-23 11:49

Shaily Engineering Plastics Limited announced an Analyst/Institutional Investor Group Meeting on March 27, 2026, from 10:00 AM onwards in Baroda, Gujarat. Discussions will be based on publicly available information.

SHAILY

Shaily Engineering Plastics Limited

Price Chart

Filing History

Unlock Full History